Area of research
Hematology · Molecular Biology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Multiple Myeloma Research and Treatments, Hematopoietic Stem Cell Transplantation, and Chronic Myeloid Leukemia Treatments.
Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
Versorgung von Patienten mit kardialer Amyloidose
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation
Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>light‐chain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up
Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis
Search for AL amyloidosis risk factors using Mendelian randomization
Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival
Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
Two-Year Evaluation of the German Clinical Amyloidosis Registry
Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation
Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance